Pharming (PHAR) Receivables - Other (2019 - 2025)

Pharming's Receivables - Other history runs 6 years deep, the most recent figure standing at $1.9 million for Q4 2025.

• Quarterly Receivables - Other rose 21.05% year-over-year to $1.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.9 million (up 21.05% YoY) and the FY2025 annual result came in at $1.9 million, up 21.05% from the prior year.
• Receivables - Other was $1.9 million for Q4 2025 at Pharming, up from $1.6 million in the prior quarter.
• Across five years, Receivables - Other topped out at $2.1 million in Q4 2023 and bottomed at $1.1 million in Q4 2022.
• A 4-year average of $1.7 million and a median of $1.8 million in 2024 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2023 — Receivables - Other soared 92.03% — and 2024, when it slipped 25.59%.
• Pharming's Receivables - Other stood at $1.1 million in 2022, then surged by 92.03% to $2.1 million in 2023, then slipped by 25.59% to $1.6 million in 2024, then rose by 21.05% to $1.9 million in 2025.
• Business Quant data shows PHAR's Receivables - Other at $1.9 million in Q4 2025, $1.6 million in Q4 2024, and $2.1 million in Q4 2023.